Feasibility of Oto-acoustic Emission assessment in identification of ototoxic hearing loss in adult individuals with cancer receiving Cisplatin based Chemo-radiotherapy. - Nil

Tata Research Administrative Council0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•Following are the inclusion criteria for enrollment of the study participants.
•1-Head-neck cancer patients who are planned to receive Cisplatin-based definitive or adjuvant chemo-radiotherapy
•2-Head-neck cancer patients who are able to provide consistent and reliable responses in conventional pure-tone audiometry.
•3-Head-neck cancer patients who have not received any known ototoxic cancer treatment before.
•4-Head-neck cancer patients without any known cognitive or psychological problems

•Following ear-wise exclusion criteria at the time of enrollment will be taken for the study.
•1-Ears of Head-neck cancer patients with air Conduction Hearing thresholds >50dBHL at any of the octave-band test frequencies between 0.5 to 8 KHz.
•2-Ears of Head-neck cancer patients with Distortion Product Oto-acoustic Emission (DPOAE)Signal to Noise Ratio (SNR) level < 6 dBSPL and/ or absolute DPOAE amplitude < -10dBSPL at any two test frequencies between 1.5 to 6KHz
•3-Ears of Head-neck cancer patients with presence of any Conductive hearing loss at baseline or at end-of-treatment evaluation.
•4-Ears of Head-neck cancer patients with a history of previous ear surgery
•5-Ears of Head-neck cancer patients with any known pre-treatment hearing loss documented in baseline audiogram.

发起方

Tata Research Administrative Council